Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilBigKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 11/20/2017 12:42:37 AM - Followers: 727 - Board type: Free - Posts Today: 1

Innovation Pharmaceuticals Inc. (IPIX)

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564

About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at


Ongoing Human Trials:
Product Pipeline:





Recent News and Press Releases:

SEC Filings (CIK:0001355250):

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f

Share Structure:  See SEC filing link above for current share structure


Cellceutix IP - Patent Filings:


Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
External Links: USPTO, USPTO Assignment, Espacenet

Investor Relations:

Following is a DAILY chart:


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) 11/13/2017 10:03:05 AM
IPIX News: Quarterly Report (10-q) 11/08/2017 04:04:57 PM
IPIX News: Notice of Effectiveness (effect) 09/22/2017 06:02:17 AM
IPIX News: Securities Registration Statement (simplified Form) (s-3) 09/11/2017 12:47:10 PM
IPIX News: Annual Report (10-k) 09/11/2017 06:04:38 AM
#203170  Sticky Note Doesn't seem at all reasonable that any person DaysOnTheBeach 11/09/17 10:51:58 AM
#202469  Sticky Note B-OM Due Diligence sox040713 11/03/17 04:42:35 PM
#200759  Sticky Note IPIX is looking for partnerships after P2's. petemantx 10/19/17 10:14:05 PM
#200267  Sticky Note Cellceutix Reports Very Encouraging Interim Analysis of Phase scottsmith 10/16/17 07:19:09 PM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#197995  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents sox040713 09/24/17 05:24:48 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#204356   Well what do you know? Citrati 11/20/17 12:42:37 AM
#204355   Pipeline Analysis As of May 2017, the F1ash 11/19/17 11:27:36 PM
#204354   Chemotherapy-Induced Oral Mucositis Treatment & Management F1ash 11/19/17 11:11:07 PM
#204353   Investing in a biotech is a long term Jhawker 11/19/17 10:40:26 PM
#204351   Actually, by the end of this week , the georgejjl 11/19/17 09:13:11 PM
#204350   Your statement sounds Leoesque, potentially we will sign alwaysdreaming 11/19/17 09:11:44 PM
#204349   This cure is as bad as the disease. TheDane 11/19/17 08:45:16 PM
#204348   Final treament should be completed last week if sox040713 11/19/17 08:22:16 PM
#204347   Great point that may be overlooked in a DaubersUP 11/19/17 05:48:24 PM
#204345   Wall Street coverage? Unlikely regardless of the scottsmith 11/19/17 04:31:07 PM
#204344   I agree Leo has almost never put out Jhawker 11/19/17 04:19:57 PM
#204343   New investors, naked shorting is almost nonexistent in sox040713 11/19/17 04:14:24 PM
#204342   Not on a Holiday week when most bigwigs petemantx 11/19/17 03:58:23 PM
#204341   I thought the news was going to be untohim 11/19/17 02:42:08 PM
#204340   Brilacidin is a company within itself! runninggirl2016 11/19/17 01:41:35 PM
#204339   I'll take the dilution over a crushing debt 58nout 11/19/17 01:06:54 PM
#204338   Who great kahuna? Also when o/s share numbers became Amatuer17 11/19/17 12:16:44 PM
#204337   By the end of this week , the final georgejjl 11/19/17 10:32:58 AM
#204336   The train may have slowed down but it's bradfordbros 11/19/17 10:30:34 AM
#204335   Yes Kimosabee you are right, especially considering IPIX'S 58nout 11/19/17 09:54:55 AM
#204334   No sarcasm handy re: the restriction to "listed companies"? loanranger 11/19/17 09:16:58 AM
#204332   to quote a recent witch hunt: sir, there untohim 11/19/17 09:15:10 AM
#204331   ahhh now the sound of crickets...... untohim 11/19/17 09:11:29 AM
#204330   in the words of the great Kahuna, not untohim 11/19/17 08:52:08 AM
#204329   Truth is that Mako did all True Longs scottsmith 11/19/17 07:53:18 AM
#204328   Excellent summary post! BP is very interested. DaubersUP 11/19/17 07:41:37 AM
#204327   “140 million shares o/s screams strong demand....” The o/s Amatuer17 11/19/17 07:03:23 AM
#204326   BP's interests in the Big Three sox040713 11/19/17 01:12:38 AM
#204325  Restored That’s what your buddy Mako said. But I sox040713 11/19/17 12:28:23 AM
#204324   It’s fake news, as usual. The judge dismissed sox040713 11/19/17 12:20:48 AM
#204323   Or how about: LilBigKahuna 11/19/17 12:07:57 AM
#204322   Even if the drugs are picked up by falcon74 11/18/17 11:16:21 PM
#204321   IPIX can't fail unless nobody wants the drugs. septmike09 11/18/17 11:02:40 PM
#204320   If one co fails next will come - Amatuer17 11/18/17 10:44:01 PM
#204319   No no no. Way too low groton68 11/18/17 10:18:49 PM
#204318   Short selling biotech stocks like IPIX is immoral georgejjl 11/18/17 10:06:02 PM
#204317   value of B alone = SP 1.70? ASK YOURSELF untohim 11/18/17 09:57:22 PM
#204316   Because if our institutional holder’s 300 shares are sox040713 11/18/17 09:16:35 PM
#204315  Restored I recommend selling and moving on for investors Cherry_11 11/18/17 09:16:22 PM
#204314   You visited ipix hq and the offices were empty? scottsmith 11/18/17 09:13:10 PM
#204312   understood hes promoting the supply demand principle of untohim 11/18/17 08:59:19 PM
#204311   Not true. The lawsuit based on Mako’s hit sox040713 11/18/17 08:57:58 PM
#204310   Number of shares outstanding and current share price Blue Fin 11/18/17 08:55:37 PM
#204309   baking 70 cents with even avg p results untohim 11/18/17 08:47:25 PM
#204308   If the market is always correct in smelling sox040713 11/18/17 08:43:02 PM
#204307   140 million shares o/s screams strong demand....along with untohim 11/18/17 08:37:40 PM
#204306   Well - 140 million o/s shares What is the Amatuer17 11/18/17 08:35:13 PM
#204305   Like “IPIX has an empty office”? sox040713 11/18/17 08:33:31 PM
#204304   Well said, those short and distort attacks started sox040713 11/18/17 08:31:10 PM
#204303   exactly....what fighting! here we are for 3 months untohim 11/18/17 08:29:07 PM